Literature DB >> 1698816

Activation and adhesion molecule expression on lymphoid infiltrates in human glioblastomas.

M C Kuppner1, M F Hamou, N de Tribolet.   

Abstract

Frozen tissue sections obtained from human glioblastomas, brain tumor metastases and normal brain were examined for the expression of molecules known to be involved in lymphocyte activation and/or adhesion and migration. The molecules studied included CD3, CD45R, UCHL-1 (CD45RO), lymphocyte function-associated antigen 1 (LFA-1) (CD11a, CD18), intercellular adhesion molecule 1 (ICAM-1) (CD54), 4B4 (CD29), CD44, CD2, and LFA-3 (CD58). CD3+ lymphocytes infiltrating human glioblastomas and brain tumor metastases expressed LFA-1 alpha and beta. Many cells were also UCHL-1+ whereas only a small percentage were CD45R+. CD2+ lymphocytes were also present. Tumor-infiltrating lymphocytes (TIL) were found to be negative for CD29, which was, however, expressed on intratumoral vessels in addition to vessels found in normal brain. Glioblastoma cells and intratumoral vessels expressed ICAM-1 whereas no ICAM-1 was found on TIL or on normal brain. Glioblastoma cells also expressed high levels of both CD44 and LFA-3 whereas TIL were negative for these antigens. CD44 was also expressed on certain regions of normal brain. Antibodies to LFA-1 alpha and -beta and ICAM-1 could significantly block the binding of lymphokine-activated killer (LAK) cells or TIL to human glioblastoma cells suggesting that these molecules play a role in the binding and subsequent migration of lymphocytes into brain tumor tissue.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698816     DOI: 10.1016/0165-5728(90)90166-k

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  12 in total

Review 1.  Expression of the CD44 adhesion molecule in tumours of the central and peripheral nervous system.

Authors:  G H Baltuch; N de Tribolet; E G Van Meir
Journal:  J Neurooncol       Date:  1995-12       Impact factor: 4.130

2.  Implementing preclinical study findings to protocol design: translational studies with alloreactive CTL for gliomas.

Authors:  Michelle J Hickey; Colin C Malone; Kate E Erickson; German G Gomez; Emma L Young; Linda M Liau; Robert M Prins; Carol A Kruse
Journal:  Am J Transl Res       Date:  2012-01-10       Impact factor: 4.060

3.  Pathogenesis of primary central nervous system lymphoma: invasion of malignant lymphoid cells into and within the brain parenchyme.

Authors:  R Aho; T Ekfors; M Haltia; H Kalimo
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

4.  Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors.

Authors:  C A Kruse; P M Schiltz; D Bellgrau; Q Kong; B K Kleinschmidt-DeMasters
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats.

Authors:  M G Kaplitt; J G Tjuvajev; D A Leib; J Berk; K D Pettigrew; J B Posner; D W Pfaff; S D Rabkin; R G Blasberg
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  Distribution of adoptively transferred, tumor-sensitized lymphocytes in the glioma-bearing rat.

Authors:  Monica R Hazelrigg; Jerry I Hirsch; Randall E Merchant
Journal:  J Neurooncol       Date:  2002-11       Impact factor: 4.130

7.  Expression and release of interleukin-1 by human glioblastoma cells in vitro and in vivo.

Authors:  T Gauthier; M F Hamou; L Monod; P Gallay; S Carrel; N de Tribolet
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

8.  Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brain.

Authors:  Michelle J Hickey; Colin C Malone; Kate L Erickson; Amy Lin; Horacio Soto; Edward T Ha; Shuichi Kamijima; Akihito Inagaki; Masamichi Takahashi; Yuki Kato; Noriyuki Kasahara; Barbara M Mueller; Carol A Kruse
Journal:  Clin Cancer Res       Date:  2013-06-18       Impact factor: 12.531

9.  Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma.

Authors:  Yalu Zhang; Qiaofei Liu; Jingkai Liu; Quan Liao
Journal:  Cancer Cell Int       Date:  2021-06-30       Impact factor: 5.722

10.  Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis.

Authors:  I Desbaillets; A C Diserens; N Tribolet; M F Hamou; E G Van Meir
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.